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DEK expression in Merkel cell
carcinoma and small cell carcinoma
Background: The chromatin architectural factor DEK maps to
chromosome 6p and is frequently overexpressed in several neoplasms,
including small cell lung carcinoma, where it is associated with poor
prognosis, tumor initiation activity and chemoresistance. DEK
expression has not been studied in cutaneous Merkel cell carcinoma.
Methods: We applied a DEK monoclonal antibody to 15 cases of
Merkel cell carcinoma and 12 cases of small cell carcinoma. DEK
nuclear immunoreactivity was scored based on percentage (0, negative;
1+, <25%; 2+, 25–50%; 3+, >50%) and intensity (weak, moderate
or strong).
Results: All 15 Merkel cell carcinoma cases (100%) showed diffuse
(3+) nuclear positivity (14 strong, 1 weak). Six of 12 small cell
carcinoma cases (50%) showed diffuse (3+) and strong nuclear
positivity, while one case exhibited focal (1+) weak nuclear positivity.
The remaining five cases were negative for DEK expression.
Conclusions: Our results suggest that DEK may be involved in the
pathogenesis of Merkel cell carcinoma and therefore may provide
therapeutic implications for Merkel cell carcinomas. In addition, the
difference in DEK expression between Merkel cell carcinoma and small
cell carcinoma suggests possible separate tumorigenesis pathways for
the two tumors.
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DEK, a highly conserved nuclear factor, is an
abundant and structurally unique constituent of
metazoan chromatin and is highly expressed in
proliferating cells.1 In vitro studies have shown that
DEK is a chromatin architectural factor and has
effects on mRNA splicing, transcriptional control,
DNA damage repair, differentiation, cell viability,
cell to cell signaling and chemoresistance.2– 5 In
the cell, these functions might be integrated by the
profound impact of DEK on heterochromatin.6
DEK also exhibits prooncogenic effects including
inhibition of p53-mediated apoptosis, cooperation
with viral oncogenes E6 and E7 to overcome senes-
cence, and promotion of HRAS-driven keratinocytic
transformation.7,8
DEK is encoded on chromosome 6p and was
initially discovered as the target of a chromosomal
translocation event t(6;9)(p23;q34) in a subset
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of acute myeloid leukemias.9 The t(6;9)(p23;q34)
translocation results in an in-frame fusion between
DEK and nucleosporin NUP214, which localizes
to the nucleoplasm.10 Expression of the DEK-
NUP214 fusion correlates with activation of
protein synthesis and phosphorylation of eIF4E, a
translational initiation factor.11 Subsequent studies
have reported DEK overexpression independent
of the t(6;9) translocation in a number of
human malignancies, including retinoblastoma,
glioblastoma, hepatocellular carcinoma, bladder
carcinoma, colon cancer, gynecologic cancers, breast
cancer, laryngeal cancer, melanoma, large cell
neuroendocrine carcinoma and small cell lung
carcinoma.3,5,12 – 19 Indeed, DEK is a key factor
in controlling the notorious chemoresistance of
melanoma.3
Merkel cell carcinoma, referred to as small cell
carcinoma of the skin, represents a rare, highly
aggressive cutaneous neuroendocrine neoplasm
with 33% mortality within 3 years of diagnosis.20
In the United States, 1500 cases of Merkel cell
carcinoma are diagnosed annually.21 From 1986 to
2001 there has been a threefold increase in Merkel
cell carcinoma cases, likely due to an expansion
of the immunosuppressed population and elevated
awareness.22 Molecular studies show trisomy 6 as the
most common chromosomal abnormality, present
in almost 50% of tumors.23
Non-cutaneous small cell carcinoma, another
highly aggressive neuroendocrine tumor, has a
dismal 5-year survival of 5–10%. Small cell
carcinoma most commonly occurs within the lung
and accounts for approximately 15% of primary lung
carcinomas.24 It also rarely occurs in extrapulmonary
sites, which typically carries a worse prognosis.
Chromosomal gain of 6p22.3, the DEK locus, in
small cell carcinoma is associated with a worse
prognosis.25
Skin lesions of Merkel cell carcinoma and
metastatic small cell carcinoma are usually indis-
tinguishable by cytomorphology, necessitating a
detailed clinical history and a panel of immunohis-
tochemical stains. Typically, Merkel cell carcinoma
is positive for CK20 and negative for thyroid tran-
scription factor (TTF)-1, while small cell carcinoma
reacts with TTF-1 but not with CK20.26 However,
there are exceptions to these staining patterns,
requiring a systemic work-up to exclude metastatic
small cell carcinoma to the skin or soft tissue. The
overexpression of DEK in small cell carcinoma
and large cell neuroendocrine carcinoma raises the
question of whether DEK could be upregulated in
Merkel cell carcinoma. In this study, we examine
the expression of DEK in Merkel cell carcinoma as
compared to small cell carcinoma.
Table 1. Summary of patient demographics for cases of Merkel cell
carcinoma and small cell carcinoma
Diagnosis n Sex (M : F) Age range (mean)
Merkel cell carcinoma 15 8 : 7 59–86 (74)
Primary 9 6 : 3 59–84 (78)
Metastatic 6 2 : 4 59–86 (78)
Small cell carcinoma 12 5 : 7 45–83 (59)
Primary 10 4 : 6 45–83 (59)
Metastatic 2 1 : 1 56–58 (57)
M, male; F, female.
Materials and methods
After University of Michigan Institutional Review
Board approval, a tissue microarray (TMA)
containing 15 well-characterized Merkel cell
carcinomas from 12 patients in triplicate was
previously constructed from archival formalin-fixed
paraffin-embedded tissue (FFPET) identified through
a retrospective search of the University of Michigan
pathology database. Nine of 15 Merkel cell carci-
noma cases were collected from primary cutaneous
excisions or excisions of locally recurrent tumors. The
remaining six specimens were collected from distant
metastases or lymph node metastases. A retrospective
search for archival FFPET blocks yield 12 cases
of well-characterized small cell carcinoma with 10
pulmonary (8 lung, 1 bronchus and 1 mediastinum)
and 2 extrapulmonary lesions (metastasis from lung
to adrenal gland and paraspinal soft tissue, respec-
tively). The original hematoxylin and eosin-stained
sections, along with available immunohistochemical
stains, were reviewed by two dermatopathologists
(L.M. and R.P.) to confirm the diagnosis. Table 1
summarizes the patient demographics.
FFPET 5-μm tissue sections from the TMA and
conventional paraffin blocks were deparaffinized
and pretreated with citrate buffer at pH 6.0.
After antigen retrieval sections were incubated with
mouse monoclonal anti-DEK antibody (1 : 400
dilution; BD Transduction Laboratories, Franklin
Lakes, NJ, USA) at room temperature for 30
min, followed by EnVision+System horseradish
peroxidase-conjugated goat anti-mouse (Dako,
Carpinteria, CA, USA) for 30 min. Sections were
then treated with peroxidase substrate solution
containing 0.01% hydrogen peroxide and 0.05%
diaminobenzidine tetrahydrochloride (Dako) and
counterstained with hematoxylin. Tonsil tissue
served as positive control.
Nuclear staining was considered positive for DEK
expression. The staining was scored and recorded
based on percentage (0 = negative, 1 = <25%,
2 = 25–50%, 3 = >50%) and intensity (weak,
moderate or strong) by two dermatopathologists
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Table 2. Percentage and intensity of DEK positive tumor cells in cases of Merkel cell carcinoma and small cell carcinoma
n Negative (%) <25% and weak (%) ≥25% and weak (%) <25% and strong (%) ≥25% and strong (%)
Merkel cell carcinoma 15 0 (0) 0 (0) 1 (6.7) 0 (0) 14 (93)
Primary 9 0 (0) 0 (0) 0 (0) 0 (0) 9 (100)
Metastatic 6 0 (0) 0 (0) 1 (17) 0 (0) 5 (83)
Small cell carcinoma 12 5 (42) 1 (8.3) 0 (0) 0 (0) 6 (50)
Primary 10 5 (50) 1 (10) 0 (0) 0 (0) 4 (40)
Metastatic 2 0 (0) 0 (%) 0 (0) 0 (0) 2 (100)
(L.M. and R.P.). The staining patterns and intensities
among three cores showed minimal variation.
Fisher’s exact test was performed to assess the
difference in DEK expression between Merkel
cell carcinoma and small cell carcinoma using
GraphPad Prism version 5.01 for Windows,
GraphPad Software, San Diego, CA, USA,
www.graphpad.com. A p-value <0.05 was consid-
ered statistically significant.
Results
In normal skin, as previously described, DEK
was expressed with moderate intensity in basilar
keratinocytes and dermal lymphocytes.27 In normal
lung tissue, DEK staining was restricted to infiltrating
lymphocytes.5
The staining pattern of DEK in Merkel cell
carcinoma and small cell carcinoma are summarized
in Table 2. All 15 cases (100%) of Merkel cell
carcinoma showed diffuse (3+) nuclear reactivity.
Nearly all cases (14/15) showed strong staining
(Fig. 1A), except that one case of metastatic Merkel
cell carcinoma exhibited weak staining. In contrast,
7 of 12 (58%) small cell carcinoma cases showed
positive DEK staining, which was significantly less
than for Merkel cell carcinoma (p < 0.05). Among
seven DEK-positive small cell carcinoma cases, six
exhibited diffuse (3+) and strong nuclear reactivity
(Fig. 1B) while one case had focal (1+) and weak
staining. Both cases of metastatic small cell carcinoma
exhibited diffuse and strong DEK staining. All five
cases of DEK-negative small cell carcinomas (Fig. 1C)
were pulmonary primary tumors with four from lung
and one from mediastinum.
Discussion
DEK represents a highly conserved nuclear factor
with function regarding chromatin and DNA dam-
age repair. The overexpression of DEK has been
reported in numerous human malignancies, includ-
ing retinoblastoma, bladder carcinoma, colon cancer
and melanoma. More recently, DEK expression was
found in high grade neuroendocrine lung cancers,
including small cell and large cell carcinomas, where
elevated DEK levels were associated with a worse
prognosis.5 In this study, we examined the expres-
sion of DEK by immunohistochemistry in Merkel cell
carcinoma in comparison with small cell carcinoma
of the lung. To our knowledge, this is the first report to
examine DEK expression in Merkel cell carcinoma.
In this study, we found an upregulation in DEK
expression in nearly all (14/15) Merkel cell carcino-
mas and about half (7/12) of small cell carcinoma
cases. Strong overexpression of DEK in our small
cell carcinoma cohort is comparable to a previous
study that showed strong overexpression of DEK
in 44.3% (35/79) of high grade neuroendocrine
lung carcinomas.5 Although there is a significant
difference in DEK expression in Merkel cell
carcinoma and small cell carcinoma, the presence of
DEK expression would be of limited diagnostic use
in distinguishing the two entities since a strong and
diffuse staining pattern may be seen in both entities.
However, the difference in DEK staining patterns
in Merkel cell carcinoma and small cell carcinoma
suggests that the two tumors may follow different
pathways in tumorigenesis. Similarly, Merkel cell
carcinoma and small cell carcinoma vary in their p63
expression patterns. Small cell carcinoma is typically
negative for p63.28 In contrast, p63 overexpression
was identified in 61% of lower stage Merkel cell
carcinomas.29 Interestingly, DEK overexpression
stimulates p63 expression at the level of mRNA and
protein synthesis. In addition, knockdown of DEK
expression results in p63 repression in a keratinocyte
cell line.30 These findings suggest the difference in
DEK expression between Merkel cell carcinoma
and small cell carcinoma may be, in part, related to
the difference in p63 expression noted between the
two entities.
DEK expression is positively regulated by the
high-risk human papilloma virus (HPV) E7 oncogene
via a decrease in the expression of retinoblastoma
protein, a tumor suppressor.7 Early DEK studies in
HPV infections showed that decreased retinoblas-
toma protein results in overexpression of DEK.7
Recently, a 5387 base pair polyomavirus genome
was discovered in 43–100% Merkel cell carcinoma
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Fig. 1. Representative DEK immunohistochemistry in Merkel cell carcinoma (A) and small cell carcinoma (B) demonstrating diffuse, strong
nuclear reactivity and in small cell carcinoma demonstrating an absence of reactivity (C).
tumors.31 – 33 The virus, named MCPyV because of
its association with Merkel cell carcinoma, integrates
into different sites of the cellular genome in different
Merkel cell carcinoma tumors and cell lines. The
MCPyV-encoded large T antigen binds retinoblas-
toma protein, which plays a vital role in Merkel
cell carcinoma tumorigenesis.34 We suspect that the
overexpression of DEK in Merkel cell carcinoma
may be a result of MCPyV genome integration and
the downregulation of retinoblastoma protein. In
contrast, MCPyV is identified in only 0–39% of
small cell carcinomas, which is significantly lower
than Merkel cell carcinomas.35 – 37
We found that the overexpression of DEK not
only in nine primary/locally recurrent tumors
but also six metastatic tumors, indicating that
the level of DEK expression probably plays no
significant role in the prognosis of Merkel cell
carcinoma. A future study with a larger cohort
and detailed clinical follow-up data is required to
confirm our initial findings. Patients with high-grade
neuroendocrine lung cancers expressing high levels
of DEK have a significantly shorter survival than
those expressing low levels of DEK (18 versus
55% overall survival after 11 years).5 In our study,
100% (2/2) of metastatic small cell carcinomas
strongly expressed DEK, whereas 44% (4/9) of
primary/recurrent tumors showed positivity. Our
findings suggest that DEK may correlate with a
more aggressive phenotype. However, a relationship
between DEK expression and clinical outcome
cannot be concluded from this study because of the
limited time course and information for follow up.
The purported role of DEK in tumorigenesis in
a number of human malignancies combined with
its high incidence of expression in Merkel cell
carcinoma makes DEK an appealing therapeutic
target. Silencing of DEK expression in small
cell lung carcinoma cell clones transplanted in
immunodeficient mice resulted in near abrogation
of tumor formation compared to parent clones.5 In
melanoma cell lines, inhibition of DEK expression
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led, among other effects, to cell cycle arrest.3 In
addition, reduction of DEK expression resulted in
increased sensitivity to chemotherapeutic agents in
small cell lung carcinoma and melanoma cell lines.3,5
The ubiquitous DEK expression in Merkel cell
carcinoma makes it an appealing candidate for DEK
suppression therapy.
In summary, DEK is diffusely and strongly
expressed in nearly all Merkel cell carcinomas
but only in half of small cell carcinomas. The
difference in DEK staining patterns between these
two neuroendocrine tumors suggests the possibility
of distinct oncogenic pathways. The frequent DEK
overexpression in Merkel cell carcinoma makes it an
appealing therapeutic target. Our study provides a
basis for a future large cohort study to investigate
the therapeutic utility of DEK in Merkel cell
carcinomas.
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